the upside, page-36

On analogies with BKL:

Blackmores chief executive Christine Holgate says while the infant formula opportunity has substantial upside, there are also plans to make a range of nutritional formulas to help older people. She says the joint venture is in its infancy and a chief executive is still to be appointed but the companies wanted to announce it so they could on with the detailed processes needed to become a strong player in infant formula, with Blackmores the lead brand on the tins.

"It was just getting too cloak and dagger," she says of the secrecy surrounding the early negotiations. Now that it is public knowledge, the infrastructure and supply arrangements with Bega would quickly be cemented ready for the first products to hit the market in early 2016.

Some analysts have a price target of $282 for BKL.

Look at the size of the markets for MSB. Look at the range of applications. Look at the fact that there are negotiations underway with multiple partners. Look at the proven science. The fast tracking to market.

Look at the risk v reward!

Of course traders (and possible shorters) want to distract with personal attacks, pseudo science and other claims.

The americans will understand this stock. Others may pretend to not understand it.

The trading suspension may be extended....meanwhile the shorters have to salvage something.  Accumulators still at it, wanting cheap shares.

Why the intensity to the discussion if this were otherwise? It makes no sense.